The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...